Europe's Innovative Medicines Initiative (IMI) selected 8 projects for funding from its fast-track call for proposals on coronavirus diagnostics and treatments. KU Leuven takes up a prominent role in the selected CARE project, involving research groups of Professors Johan Neyts, Isabelle Huys and Nico Vandaele. The KU Leuven Centre for Drug Design and Discovery (CD3) is also involved.
The goal of the CARE project is to deliver treatments for current as well as future coronavirus outbreaks. To do this, they will identify candidates among existing drugs that could be effective as treatments for the COVID-19 pandemic, and develop new drugs specially designed to tackle the SARS-CoV-2 virus. After extensive testing in the laboratory, the project will advance the most promising drug candidates to clinical trials in humans.
This article was first published on 14 May by KU Leuven.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
